Incannex Healthcare (NASDAQ: IXHL) sets Clinical Advisory Board for PSX-001

Rhea-AI Filing Summary

Incannex Healthcare Inc. filed a current report to note a corporate development related to its PSX-001 program. On January 22, 2026, the company announced it has formed a Clinical Advisory Board to support this program, indicating a step toward organizing expert guidance around its clinical strategy. Details about the advisory board’s members, role, and expected contributions are provided in a press release dated January 22, 2026, which is attached to the report as Exhibit 99.1.

false 0001873875 0001873875 2026-01-22 2026-01-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 22, 2026

Incannex Healthcare Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41106		93-2403210
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Rialto South Tower Level 23, 525 Collins Street Melbourne, VIC 3008 Australia		Not applicable
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, including Area Code: +61 409 840 786

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, $0.0001 par value per share		IXHL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 22, 2026, Incannex Healthcare Inc. Announces Formation of Clinical Advisory Board for PSX-001 Program. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Incannex Healthcare Inc., dated January 22, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Incannex Healthcare Inc.
Date: January 22, 2026		/s/ Joel Latham
	Name:	Joel Latham
	Title:	Chief Executive Officer and President

 2

FAQ

What did Incannex Healthcare Inc. (IXHL) announce in this 8-K filing?

Incannex Healthcare Inc. reported that on January 22, 2026 it announced the formation of a Clinical Advisory Board for its PSX-001 program, as described in a press release attached as Exhibit 99.1.

Which program at Incannex Healthcare Inc. (IXHL) is linked to the new Clinical Advisory Board?

The new Clinical Advisory Board is associated with Incannex Healthcare Inc.’s PSX-001 program, according to the current report.

Where can investors find more details about Incannex Healthcare Inc.’s PSX-001 Clinical Advisory Board?

More details are contained in the press release dated January 22, 2026, which is included as Exhibit 99.1 to the report.

What exhibits did Incannex Healthcare Inc. (IXHL) include with this 8-K?

The filing includes Exhibit 99.1, a press release dated January 22, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Does this Incannex Healthcare Inc. (IXHL) filing report any financial results?

No financial results are described. The report focuses on an other event under Item 8.01, specifically the formation of the Clinical Advisory Board for the PSX-001 program.

Who signed this Incannex Healthcare Inc. (IXHL) 8-K filing?

The report was signed on behalf of Incannex Healthcare Inc. by Joel Latham, who is identified as the Chief Executive Officer and President.